Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Shares Outstanding (Weighted Average) (2019 - 2025)

Avidity Biosciences' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $137.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 23.42% year-over-year to $137.7 million; the TTM value through Dec 2025 reached $137.7 million, up 23.42%, while the annual FY2025 figure was $137.7 million, 23.42% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $137.7 million in Q4 2025 per RNA's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $137.7 million in Q4 2025 to a low of $6.8 million in Q3 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $73.3 million, with a median of $70.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 1218.84% in 2021, then plummeted 93.56% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $41.4 million in 2021, then rose by 25.91% to $52.2 million in 2022, then surged by 39.97% to $73.0 million in 2023, then surged by 52.83% to $111.6 million in 2024, then grew by 23.42% to $137.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Shares Outstanding (Weighted Average) are $137.7 million (Q4 2025), $6.8 million (Q3 2025), and $129.6 million (Q2 2025).